Prenetics Global Limited
HealthcareNASDAQ:PRE · NASDAQ Global Market
+$0.94 today
Vol 0.35M · Avg 0.22M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$113.7M of revenue converted into -$71.0M of net income for the selected period. Gross margin is 56.2% and net margin is -60.7%, showing how much revenue survives after costs and taxes. EPS is $-4.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.4M +201.7% | $30.6M +40.8% | $21.7M +65.2% | $13.2M +5.0% | $12.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $43.6M +186.4% | $15.2M +17.9% | $12.9M +35.3% | $9.5M +6.9% | $8.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $48.8M +216.8% | $15.4M +74.4% | $8.8M +144.1% | $3.6M +0.4% | $3.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 52.8% +2.5pp | 50.3% +9.7pp | 40.6% +13.1pp | 27.5% -1.3pp | 28.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $5.1M -53.0% | $10.9M -6.3% | $11.7M +94.7% | $6.0M -6.3% | $6.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $79.8M +44.1% | $55.4M +11.4% | $49.7M -22.5% | $64.1M +19.4% | $53.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $86.9M +36.8% | $63.5M +4.6% | $60.7M -12.8% | $69.6M +15.6% | $60.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.8M -36.2% | $5.9M -23.9% | $7.8M +3.3% | $7.5M +2.7% | $7.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$32.2M +37.6% | -$51.6M -7.7% | -$47.9M +78.0% | -$218.0M -4.2% | -$209.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -34.8% +133.6pp | -168.4% +51.9pp | -220.3% +1436.0pp | -1656.3% +12.6pp | -1668.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$38.1M +20.8% | -$48.1M +7.2% | -$51.9M +21.4% | -$66.0M -16.5% | -$56.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -41.3% +116.0pp | -157.2% +81.5pp | -238.7% +262.8pp | -501.5% -49.4pp | -452.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.0M -48.9% | $2.0M -48.0% | $3.9M +731.2% | $472.0K +234725.9% | $201 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $241.0K +18.7% | $203.0K +69.6% | $119.7K -50.6% | $242.0K +473.1% | $42.2K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.9M +120.0% | -$9.6M -100.7% | -$4.8M +97.0% | -$159.8M +0.1% | -$159.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$36.2M +37.2% | -$57.7M -1.8% | -$56.7M +74.9% | -$225.8M -4.3% | -$216.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -39.2% +149.2pp | -188.4% +72.2pp | -260.6% +1454.8pp | -1715.4% +12.5pp | -1727.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $34.0K +100.4% | -$7.9M -2823.2% | -$269.4K -9.9% | -$245.0K -109.5% | $2.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$37.7M +18.6% | -$46.3M +26.2% | -$62.7M +67.1% | -$190.5M -9.5% | -$174.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -40.8% +110.4pp | -151.2% +137.3pp | -288.5% +1158.3pp | -1446.8% -58.3pp | -1388.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +26.4% | -$4 +34.8% | -$6 +85.1% | -$38 +20.1% | -$47 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +26.4% | -$4 +34.8% | -$6 +85.1% | -$38 +20.1% | -$47 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $14.1M +10.6% | $12.7M +13.0% | $11.2M +121.8% | $5.1M +37.0% | $3.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $14.1M +10.6% | $12.7M +13.0% | $11.2M +121.8% | $5.1M +37.0% | $3.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$62.14M
Atlantic International Corp.
NASDAQ:ATLN
$47.61M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRE generate?
Prenetics Global Limited (PRE) reported $92.39M of revenue in fiscal 2025.
Is PRE profitable?
Prenetics Global Limited (PRE) reported -$37,709,000.00 of net income, with a net margin of -40.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.